Pacific Biosciences

PACB

Market cap $535M

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.59, marking a -1.85% move from the previous day.

New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale

More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine

PACB's Q2 beat, expanding Revio and Vega systems and growing clinical traction highlight its innovation-led recovery despite longer purchasing cycles.

PACB expands seqWell partnership to enhance its sequencing workflow offerings with a new multiplexing kit.

Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio's Revio system, powering one of the largest studies of healthy aging to date Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio's Revio system, powering one of the largest studies of healthy aging to date

Highly scalable, cost-effective LongPlex™ kit delivers streamlined tagmentation and multiplexing for low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing Highly scalable, cost-effective LongPlex™ kit delivers streamlined tagmentation and multiplexing for low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.52, marking a +2.01% move from the previous day.

PACB expands its PureTarget portfolio, streamlining carrier screening with HiFi sequencing to meet rising global demand.

In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.29, indicating a +1.57% shift from the previous trading day.